Stomach Cancer Treatment in China: Advanced Disease, Satri-cel Screen and Costs

Gastric and GEJ cancer care in China: standard multimodal treatment, HER2 and Claudin18.2 testing, the narrow satri-cel CAR-T indication, named centres, and realistic stage-4 goals — not a universal solid-tumour cell offer.

7500+

patients treated

10

years of experience

50+

partner clinics

Stomach: standard GI care vs a narrow cell door

Satri-cel is not the default gastric plan. Most files stay on surgery and systemic therapy. The cell door opens only if all four boxes are true.

Claudin18.2-positive on a real report
HER2-negative
Advanced gastric or GEJ adenocarcinoma
At least two prior systemic lines
PathwayUsual deskPlanning figure
Resectable / perioperative / standard advancedFudan, SYSUCC, CAMS/NCCNo single band — drugs and stay
Satri-cel screen (label match)PKU Cancer / designated CAR-TProduct ~RMB 990k / USD 146k + stay/CRS
Other solid-tumour CAR-T / TILTrial onlyNot a walk-in product
Fuda as first clickCompare method with SYSUCCNot a satri-cel substitute

CAR-T / satri-cel · Cost letter checklist · Hospitals

What the medical trip includes

  • 📋

    HER2 and Claudin18.2 on the file

    Without those, we will not treat a satri-cel screenshot as eligibility.

  • 🏥

    GI unit vs designated CAR-T room

    Fudan/SYSUCC/CAMS for standard gastric care. PKU Cancer when the label screen is real.

  • ✈️

    Stage-4 goals before flights

    Control vs an actual cell-therapy screen. Two different trips, two different bills.

Why patients choose us

  • ✅

    Satri-cel kept narrow

    Four criteria, not a solid-tumour slogan. We say no when the file misses one.

  • 💬

    Standard gastric care still first

    Most patients need surgery/systemic sequencing, not a cell product.

  • 🌍

    Same RMB 990k figure as CAR-T/cost

    We do not invent a cheaper gastric CAR-T number for this URL.

How it works

  • 01

    Send pathology and line history

    HER2 now; Claudin18.2 if satri-cel is the question.

  • 02

    Split standard vs cell screen

    Most files stay on multimodal GI oncology. A minority meet the satri-cel label.

  • 03

    Travel after the right desk accepts

    GI unit or designated CAR-T centre — not a mixed Guangzhou brochure.

Treatment package costs

  • Gastric file review

    No charge to start

    Stage/line read • Satri-cel label check • Centre split • Cost-driver note

  • Coordinated trip

    Quoted after records

    GI or CAR-T desk matching • Itemised drivers • Visa • Interpreter

Who this is for

  • Advanced / stage-4 gastric or GEJ

    Need honest control options and a biomarker checklist, not a cure landing page.

  • Patients who arrived via satri-cel news

    Need the four-point label applied to their own report before anyone quotes cells.

  • Resectable or perioperative patients

    Need a high-volume GI unit, not a cellular-therapy advertisement.

Frequently asked questions

  • Is stage 4 stomach cancer treated in China?

    Yes. Systemic therapy, selected local control, and — if the label matches — a satri-cel screen. Goals for advanced disease are often control and symptoms. We do not promise a cure.

  • What is satri-cel for gastric cancer?

    A Claudin18.2-directed CAR-T reported as approved in 2026 for HER2-negative advanced gastric or GEJ cancer after at least two prior lines. Not for all gastric tumours. Eligibility is hospital-decided. Details on the CAR-T page.

  • Do I need Claudin18.2 testing before I travel?

    If satri-cel is why you are looking at China, yes — plus HER2 and a complete line history. Flying first and testing later wastes a visa.

  • Which hospitals for stomach cancer?

    PKU Cancer for satri-cel screens; CAMS/NCC, Fudan, SYSUCC for standard gastric oncology. Compare Fuda only on the actual method, not the brand.

  • How much does treatment cost?

    Standard multimodal care has no single band — drugs and stay dominate. Satri-cel product-only planning figures around RMB 990,000 plus admission/toxicity. Public vs private CAR-T bands on the cost page apply only if you are actually on a cell pathway.

  • Are stage-4 reviews reliable online?

    Only if they ask for pathology, biomarkers and prior lines. A page that promises reversal of stage 4 gastric cancer is not a review.

  • What documents matter most?

    Pathology, HER2, Claudin18.2 if seeking satri-cel, staging imaging, and every prior systemic line with dates and response.

More about treatment in China

Stomach cancer treatment in China splits into ordinary high-volume GI oncology and a very small cellular door. Standard care is still surgery when resectable, perioperative or palliative chemo, HER2-targeted therapy when HER2-positive, checkpoint inhibitors in selected PD-L1 or MSI groups, and supportive care. Stage 4 is treated; the honest goal is often control, not a cure slogan. Satri-cel is the exception people now search for. Public reports describe a 2026 NMPA approval for Claudin18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma after at least two prior systemic lines. That is not CAR-T for every stomach cancer and not CAR-T for every solid tumour. Without Claudin18.2 and HER2 on the file, a satri-cel travel quote is marketing. Product-only planning figures around RMB 990,000 (about USD 146,000) exclude admission, lymphodepletion and toxicity — see the CAR-T and cost pages. Centres: Peking University Cancer Hospital for satri-cel / CT041 discussions; CAMS/NCC, Fudan, SYSUCC for high-volume gastric surgery and systemic care; Ruijin when haematology/CAR-T infrastructure is the question. Fuda is not a substitute for a Claudin18.2-labelled programme. Send endoscopy/pathology, HER2, Claudin18.2 if available, staging CT/PET, and the full line history.
Home
Menu
Search
Инфо